Literature DB >> 22525156

Colorectal cancer screening: why immunochemical faecal occult blood test performs as well with either one or two samples.

Lydia Guittet1, Véronique Bouvier, Elodie Guillaume, Romuald Levillain, Angela Ruiz, Olivier Lantieri, Guy Launoy.   

Abstract

BACKGROUND: Immunochemical faecal occult blood tests perform as well with either one or two samples, and better than guaiac tests with 6 samples. AIMS: Clarifying relationship between tests' performance, bleeding pattern and observation level.
METHODS: The data of 32,225 average-risk subjects who performed both Hemoccult II (guaiac) and Magstream (immunochemical) tests were re-analysed by varying the cutoff and number of samples of Magstream.
RESULTS: The identical performances obtained using one or two samples of Magstream (lower cutoff for one sample) at the population level were explained by opposite patterns of bleeding according to the presence of advanced neoplasias. They translated into discrepancy at the individual level: for example a 60% increase in sensitivity and 20% in specificity observed with one (39ng Hb/ml cutoff) or two samples (63ng Hb/ml cutoff) Magstream compared with Hemoccult II meant that 28.5% of the subjects testing positive with one sample (18.0% in subjects with advanced neoplasias) would have been considered negative by using two samples of Magstream at a higher cutoff (and reciprocal).
CONCLUSION: The identical performance of immunochemical tests using one or two samples (different cutoff), explained by opposite pattern of bleeding according to advanced neoplasias is true only at the population level, the appropriate level for mass screening.
Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525156     DOI: 10.1016/j.dld.2012.03.005

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Fecal immunochemical test accuracy in average-risk colorectal cancer screening.

Authors:  Vicent Hernandez; Joaquin Cubiella; M Carmen Gonzalez-Mao; Felipe Iglesias; Concepción Rivera; M Begoña Iglesias; Lucía Cid; Ines Castro; Luisa de Castro; Pablo Vega; Jose Antonio Hermo; Ramiro Macenlle; Alfonso Martínez-Turnes; David Martínez-Ares; Pamela Estevez; Estela Cid; M Carmen Vidal; Angeles López-Martínez; Elisabeth Hijona; Marta Herreros-Villanueva; Luis Bujanda; Jose Ignacio Rodriguez-Prada
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 2.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

Review 3.  Colorectal cancer screening: tests, strategies, and perspectives.

Authors:  Fabrizio Stracci; Manuel Zorzi; Grazia Grazzini
Journal:  Front Public Health       Date:  2014-10-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.